Bay Area's second IPO of the year hits top of targets, raises $238M

Revolution Medicines Inc. hit the top of the IPO target range it boosted this week, raising $238 million as it gets set to begin trading on Thursday. The Redwood City oncology biotech, led by CEO and President Mark Goldsmith, agreed to sell 14 million shares at $17 apiece, giving it an initial market cap of about $967 million going into its Wall Street debut. Insiders have options to buy about 2.1 million more shares at the offering price. The plan until this week was to sell 10 million shares…